FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967210005> ?p ?o ?g. }

• W1967210005 endingPage "687" @default.
• W1967210005 startingPage "680" @default.
• W1967210005 abstract "Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR). The recommended dosage is an initial load of 400 mg/m² intravenously (IV) followed by a weekly maintenance dose of 250 mg/m². It has been reported retrospectively that cetuximab efficacy was correlated with dose-related severity of skin rash. This study was prospectively designed to examine the safety and feasibility of escalating weekly doses of cetuximab, testing the hypothesis of the relationship of dose-dependent skin toxicity and efficacy. Methods Four dose levels were tested: Cetuximab 400 mg/m² IV loading dose and 250, 300, 350, 400 mg/m² weekly IV maintenance. There was no intra-patient dose escalation. Standard dose limiting toxicity criteria were used. Rash was evaluated using two additional validated dermatology methods: global acne grading scale (GAGS) and acne lesion counting (ALC). Tumor specimens and blood samples were obtained for correlative analyses.Twenty seven patients with solid tumors were enrolled: five head and neck, three pancreas, four gall bladder, two each of prostate, breast, colorectal, lung, and esophagus, and five others. Planned dose escalation was completed without reaching dose-limiting toxicity (DLT) or the maximum tolerated dose (MTD). The highest dose level was expanded to a total of 17 patients. Gr 3/4 toxicities included: lymphopenia (2), fatigue (2), and hypomagnesemia (2). One patient experienced a grade 3 rash (350 mg/m²). Sixty five percent of pts had a ≥ Gr 2 rash that was not dose dependent. In 22 evaluable patients, there was one partial response (PR) in a patient with cholangiocarcinoma (400 mg/m²) and seven patients had stable disease (SD). ALC and GAGS demonstrated no correlation with dose or response. Correlative studies evaluating k-ras, EGFR FISH status and immunologic correlatives were conducted on available tumor samples.Cetuximab administered at 400 mg/m² IV as a loading dose with weekly maintenance dose of 400 mg/m² is feasible and well tolerated. There was no direct correlation of the grade of rash with dose in this group of patients with heterogenous solid tumors." @default.
• W1967210005 created "2016-06-24" @default.
• W1967210005 creator A5010265482 @default.
• W1967210005 creator A5022600472 @default.
• W1967210005 creator A5032197991 @default.
• W1967210005 creator A5035562927 @default.
• W1967210005 creator A5036091074 @default.
• W1967210005 creator A5038007841 @default.
• W1967210005 creator A5044249948 @default.
• W1967210005 creator A5059185125 @default.
• W1967210005 creator A5068073376 @default.
• W1967210005 creator A5070878175 @default.
• W1967210005 creator A5075902185 @default.
• W1967210005 creator A5080292686 @default.
• W1967210005 date "2010-02-12" @default.
• W1967210005 modified "2023-10-16" @default.
• W1967210005 title "Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study" @default.
• W1967210005 cites W1967054917 @default.
• W1967210005 cites W1968151389 @default.
• W1967210005 cites W1971883262 @default.
• W1967210005 cites W2019071322 @default.
• W1967210005 cites W2037333501 @default.
• W1967210005 cites W2039633811 @default.
• W1967210005 cites W2093207065 @default.
• W1967210005 cites W2132528753 @default.
• W1967210005 cites W2139248078 @default.
• W1967210005 cites W2409420104 @default.
• W1967210005 cites W4385789423 @default.
• W1967210005 doi "https://doi.org/10.1007/s10637-010-9396-4" @default.
• W1967210005 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4559347" @default.
• W1967210005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20148348" @default.
• W1967210005 hasPublicationYear "2010" @default.
• W1967210005 type Work @default.
• W1967210005 sameAs 1967210005 @default.
• W1967210005 citedByCount "10" @default.
• W1967210005 countsByYear W19672100052012 @default.
• W1967210005 countsByYear W19672100052013 @default.
• W1967210005 countsByYear W19672100052014 @default.
• W1967210005 countsByYear W19672100052016 @default.
• W1967210005 countsByYear W19672100052021 @default.
• W1967210005 countsByYear W19672100052022 @default.
• W1967210005 crossrefType "journal-article" @default.
• W1967210005 hasAuthorship W1967210005A5010265482 @default.
• W1967210005 hasAuthorship W1967210005A5022600472 @default.
• W1967210005 hasAuthorship W1967210005A5032197991 @default.
• W1967210005 hasAuthorship W1967210005A5035562927 @default.
• W1967210005 hasAuthorship W1967210005A5036091074 @default.
• W1967210005 hasAuthorship W1967210005A5038007841 @default.
• W1967210005 hasAuthorship W1967210005A5044249948 @default.
• W1967210005 hasAuthorship W1967210005A5059185125 @default.
• W1967210005 hasAuthorship W1967210005A5068073376 @default.
• W1967210005 hasAuthorship W1967210005A5070878175 @default.
• W1967210005 hasAuthorship W1967210005A5075902185 @default.
• W1967210005 hasAuthorship W1967210005A5080292686 @default.
• W1967210005 hasBestOaLocation W19672100052 @default.
• W1967210005 hasConcept C121608353 @default.
• W1967210005 hasConcept C126322002 @default.
• W1967210005 hasConcept C126894567 @default.
• W1967210005 hasConcept C16005928 @default.
• W1967210005 hasConcept C2777673923 @default.
• W1967210005 hasConcept C2777714996 @default.
• W1967210005 hasConcept C2778570526 @default.
• W1967210005 hasConcept C2779524853 @default.
• W1967210005 hasConcept C2779998722 @default.
• W1967210005 hasConcept C29730261 @default.
• W1967210005 hasConcept C526805850 @default.
• W1967210005 hasConcept C71924100 @default.
• W1967210005 hasConcept C90924648 @default.
• W1967210005 hasConceptScore W1967210005C121608353 @default.
• W1967210005 hasConceptScore W1967210005C126322002 @default.
• W1967210005 hasConceptScore W1967210005C126894567 @default.
• W1967210005 hasConceptScore W1967210005C16005928 @default.
• W1967210005 hasConceptScore W1967210005C2777673923 @default.
• W1967210005 hasConceptScore W1967210005C2777714996 @default.
• W1967210005 hasConceptScore W1967210005C2778570526 @default.
• W1967210005 hasConceptScore W1967210005C2779524853 @default.
• W1967210005 hasConceptScore W1967210005C2779998722 @default.
• W1967210005 hasConceptScore W1967210005C29730261 @default.
• W1967210005 hasConceptScore W1967210005C526805850 @default.
• W1967210005 hasConceptScore W1967210005C71924100 @default.
• W1967210005 hasConceptScore W1967210005C90924648 @default.
• W1967210005 hasIssue "4" @default.
• W1967210005 hasLocation W19672100051 @default.
• W1967210005 hasLocation W19672100052 @default.
• W1967210005 hasLocation W19672100053 @default.
• W1967210005 hasLocation W19672100054 @default.
• W1967210005 hasOpenAccess W1967210005 @default.
• W1967210005 hasPrimaryLocation W19672100051 @default.
• W1967210005 hasRelatedWork W1849106730 @default.
• W1967210005 hasRelatedWork W1967210005 @default.
• W1967210005 hasRelatedWork W1974386387 @default.
• W1967210005 hasRelatedWork W2034855173 @default.
• W1967210005 hasRelatedWork W2320234166 @default.
• W1967210005 hasRelatedWork W2487634586 @default.
• W1967210005 hasRelatedWork W2547152897 @default.
• W1967210005 hasRelatedWork W2791351528 @default.
• W1967210005 hasRelatedWork W2953327475 @default.
• W1967210005 hasRelatedWork W2111225769 @default.

• next